Use of ZT-1A and analogs thereof to prevent and/or treat neurodegenerative and neurocognitive disorders

US11925611B2 · kind B2 · utility

Assignees

• United States Government as represented by the Department of Veterans Affairs · US
• University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventors

• Dandan Sun · Hefei, CN
• Mohammad Iqbal Hossain Bhuiyan · Pittsburgh, US

Key dates

• Filing date: Mar 25, 2022
• Grant date: Mar 12, 2024
• Expiry date: Mar 25, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is concerned with substituted N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds, and methods of treating and/or preventing neurodegenerative or neurocognitive disorders including, but not limited to, Alzheimer's disease, cerebral autosomal dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy (CADASIL), Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS/Lou Gehrig's disease), Multiple Sclerosis, spinal muscular atrophy, spinal and bulbar muscular atrophy, familial spastic paraparesis, Machado Joseph disease, Friedreich's ataxia, Lewy body disease, and dementia (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia, mixed dementia, dementia induced by Alzheimer's disease or Parkinson's disease). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.